Revolution Medicines, Inc. Warrant (RVMDW NASDAQ) stock market data APIs
$0.31
0.02(6.5%)
as of September 17, 2025
Try our APIs with
free plan!
Revolution Medicines, Inc. Warrant Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
0.31
Open
0.3316
High
0.3316
Low
0.2701
52 wk Range
0.0305-0.8
Market Cap
0
Revenue
742 K
Beta
1.116
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines, Inc. Warrant data using free add-ons & libraries
Get Revolution Medicines, Inc. Warrant Fundamental Data
Revolution Medicines, Inc. Warrant Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -890 700 032
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines, Inc. Warrant News
New
Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results
Revolution Medicines recently showcased significant updates in its clinical trials for daraxonrasib, particularly in treating metastatic pancreatic ductal adenocarcinoma. This positive update correspo...
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability High...
Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway?
Truist Financial recently initiated coverage on Revolution Medicines with a Buy rating, highlighting the company's advancements in therapies targeting RAS-mutant cancers and the potential of its lead ...
Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress
Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the best mid-cap stocks with huge upside potential. Oppenheimer reaffirmed its Outperform rating and $75 price target for Revolution Medicines, Inc...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
